R. Spinelli

619 total citations
18 papers, 503 citations indexed

About

R. Spinelli is a scholar working on Oncology, Genetics and Pharmacology. According to data from OpenAlex, R. Spinelli has authored 18 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Genetics and 4 papers in Pharmacology. Recurrent topics in R. Spinelli's work include Estrogen and related hormone effects (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Cancer Treatment and Pharmacology (3 papers). R. Spinelli is often cited by papers focused on Estrogen and related hormone effects (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Cancer Treatment and Pharmacology (3 papers). R. Spinelli collaborates with scholars based in Italy, Netherlands and United States. R. Spinelli's co-authors include M.G. Jannuzzo, Cinzia Pellizzoni, Italo Poggesi, Daniela Fraier, Maurizio Rocchetti, B. Laffranchi, Mariangela Mariani, Jaap Verweij, E. Di Salle and Giovanna Guiso and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Biochemical Pharmacology.

In The Last Decade

R. Spinelli

18 papers receiving 480 citations

Peers

R. Spinelli

ONCOL

BIOMA

GENET

Beth Hollister United States

Tadashi Asakura Japan

Vikas V. Dukhande United States

Tomoyuki Hisa Japan

Weixian Min Canada

Mia C. Åkerfeldt Australia

Marika Salvalaio Italy

Shey-Cherng Tzou Taiwan

Marcian E. Van Dort United States

Eun-Jin Yun United States

Beth Hollister United States

R. Spinelli

299 ×1.5

184 ×1.1

ONCOL

152 ×1.2

BIOMA

56 ×0.6

20 ×0.3

GENET

Citations per year, relative to R. Spinelli R. Spinelli (= 1×) peers Beth Hollister

Countries citing papers authored by R. Spinelli

Since Specialization

Citations

This map shows the geographic impact of R. Spinelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Spinelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Spinelli more than expected).

Fields of papers citing papers by R. Spinelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Spinelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Spinelli. The network helps show where R. Spinelli may publish in the future.

Co-authorship network of co-authors of R. Spinelli

This figure shows the co-authorship network connecting the top 25 collaborators of R. Spinelli. A scholar is included among the top collaborators of R. Spinelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Spinelli. R. Spinelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Rosen, Peter J., A. W. Tolcher, R. Spinelli, et al.. (2010). Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3066–3066. 2 indexed citations

Laffranchi, B., Maja J. De Jonge, E. Bajetta, et al.. (2010). Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).. Journal of Clinical Oncology. 28(15_suppl). e13558–e13558. 6 indexed citations

Steeghs, Neeltje, Ferry A.L.M. Eskens, Hans Gelderblom, et al.. (2009). Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology. 27(30). 5094–5101. 91 indexed citations

Jannuzzo, M.G., E. Di Salle, R. Spinelli, et al.. (2008). Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Research and Treatment. 113(3). 491–499. 20 indexed citations

Cohen, Richard B., Suzanne F. Jones, Margaret von Mehren, et al.. (2008). Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 2520–2520. 11 indexed citations

Jonge, Maja J.A. de, Neeltje Steeghs, Jaco J. Verweij, et al.. (2006). 27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors. European Journal of Cancer Supplements. 4(12). 12–12. 7 indexed citations

Valle, Marta, E. Di Salle, M.G. Jannuzzo, et al.. (2005). A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. British Journal of Clinical Pharmacology. 59(3). 355–364. 39 indexed citations

Bissett, D., J Cassidy, Johann S. de Bono, et al.. (2004). Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). British Journal of Cancer. 91(1). 50–55. 92 indexed citations

Poggesi, Italo, et al.. (2004). The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemotherapy and Pharmacology. 53(6). 475–481. 20 indexed citations

10.

Jannuzzo, M.G., E. Di Salle, R. Spinelli, et al.. (2004). Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women. Journal of Clinical Oncology. 22(14_suppl). 2041–2041. 2 indexed citations

11.

Kesteren, Charlotte van, Hilde Rosing, Jan A. Lieverst, et al.. (2002). A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. British Journal of Cancer. 87(6). 608–614. 87 indexed citations

12.

Fokkema, Eelco, Jaap Verweij, A.T. van Oosterom, et al.. (2000). A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. British Journal of Cancer. 82(4). 767–771. 9 indexed citations

13.

Jannuzzo, M.G., et al.. (1999). Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV). European Journal of Cancer. 35. S294–S294. 8 indexed citations

14.

Spinelli, R., et al.. (1999). Pharmacokinetics (PK) of Aromasin® (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). European Journal of Cancer. 35. S295–S295. 24 indexed citations

15.

Nicolini, Andrea, Paola Ferrari, R. Spinelli, et al.. (1996). Cell-mediated immunity in breast cancer patients. Biomedicine & Pharmacotherapy. 50(8). 337–342. 16 indexed citations

16.

Guiso, Giovanna, et al.. (1991). Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 563(2). 323–332. 22 indexed citations

17.

Spinelli, R., Claudia Fracasso, Giovanna Guiso, Silvio Garattini, & Silvio Caccia. (1988). Disposition of (—)-fenfluramine and its active metabolite, (—)-norfenfluramine in rat: A single dose-proportionality study. Xenobiotica. 18(5). 573–584. 15 indexed citations

18.

Bettini, Ezio, Angelo Ceci, R. Spinelli, & R. Samanin. (1987). Neuroleptic-like effects of the ι-isomer of fenfluramine on striatal dopamine release in freely moving rats. Biochemical Pharmacology. 36(14). 2387–2391. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact